Takeaway
- Widespread HPV vaccination, cervical screening from 2020 may potentially avert 12.5M-13.4M cervical cancer cases by 2069 to achieve annual incidence of 4 cases/100,000 or less for all country Human Development Index (HDI) categories by century’s end.
- Assumes 80%-100% vaccination coverage is achieved for girls aged 12-15 years, all women are offered screening twice in their lifetime scaled up to 70% coverage globally.
Why this matters
- Reinforce importance of screening, HPV vaccine series uptake/completion in all eligible female patients.
Key results
- Cervical cancer expected to increase from 600K to 1.3M (2020-69), yielding 44.4M new cases, with two-thirds of burden in low-, medium-HDI countries.
- Rapid scale-up (80%-90% coverage with nonvalent vaccine [Gardasil 9]) would avert 6.7M-7.7M cases (15%-17% reduction), but >50% averted from 2060 to 2069.
- Vaccine plus 2 additional screenings would avert 5.7M-5.8M cases, resulting in 12.5M-13.4M cases averted (28%-30% reduction) for total incidence of 4 cases/100,000 from 2055 to 2059 (very-high-HDI) to 2090-2100 (low-HDI).
Study design
- Statistical trends analysis modeling study quantifying cumulative potential effects of increased global HPV vaccination and screening from 2020 to 2069.
- Funding: National Health and Medical Research Council Australia.
Limitations
- Simplified assumptions (vaccine rates, cross-protection, geographical differences in sexual behavior, population standardization, catch-up vaccine, underestimated timelines for very-high-/high-HDI countries).
Only healthcare professionals with a Univadis account have access to this article.
You have reached your limit of complementary articles
Free Sign Up Available exclusively to healthcare professionalsLogin to
account
Don’t have an account? Get started